Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)
Historic Operating Leases for Heron Therapeutics (HRTX) over the last 7 years, with Q3 2025 value amounting to $780000.0.
- Heron Therapeutics' Operating Leases rose 4942.53% to $780000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $780000.0, marking a year-over-year increase of 4942.53%. This contributed to the annual value of $2.8 million for FY2023, which is 4908.17% down from last year.
- Heron Therapeutics' Operating Leases amounted to $780000.0 in Q3 2025, which was up 4942.53% from $1.5 million recorded in Q2 2025.
- Over the past 5 years, Heron Therapeutics' Operating Leases peaked at $13.8 million during Q1 2021, and registered a low of $522000.0 during Q3 2024.
- Its 5-year average for Operating Leases is $5.5 million, with a median of $4.8 million in 2023.
- In the last 5 years, Heron Therapeutics' Operating Leases tumbled by 8524.17% in 2024 and then soared by 4942.53% in 2025.
- Over the past 5 years, Heron Therapeutics' Operating Leases (Quarter) stood at $8.0 million in 2021, then plummeted by 31.23% to $5.5 million in 2022, then tumbled by 49.08% to $2.8 million in 2023, then crashed by 81.36% to $522000.0 in 2024, then surged by 49.43% to $780000.0 in 2025.
- Its Operating Leases stands at $780000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $522000.0 for Q3 2024.